Literature DB >> 11350540

Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions.

M G Brunstein, P Belmonte-de-Abreu, D O Souza, D R Lara.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11350540     DOI： 10.1046/j.1365-2710.2001.00335.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN： 0269-4727            Impact factor:   2.512


× No keyword cloud information.
  4 in total

Review 1.  Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.

Authors:  Diogo R Lara
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 2.  Adenosine and autism: a spectrum of opportunities.

Authors:  Susan A Masino; Masahito Kawamura; Jessica L Cote; Rebecca B Williams; David N Ruskin
Journal:  Neuropharmacology       Date:  2012-08-24       Impact factor: 5.250

3.  Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.

Authors:  Jie Zhang; Chadi G Abdallah; Junqing Wang; Xiaona Wan; Chunlian Liang; Liyun Jiang; Yuzhen Liu; Haixing Huang; Xiaohong Hong; Qingjun Huang; Renhua Wu; Chongtao Xu
Journal:  Psychiatry Res       Date:  2012-06-16       Impact factor: 3.222

4.  Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.

Authors:  Ikwunga Wonodi; Hirekatur V Gopinath; Judy Liu; Helene Adami; L Elliot Hong; Robert Allen-Emerson; Robert P McMahon; Gunvant K Thaker
Journal:  Psychopharmacology (Berl)       Date:  2011-05-03       Impact factor: 4.530
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.